J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
This article was originally published in The Tan Sheet
Executive Summary
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.